Hypertrophic obstructive cardiomyopathy-a cardiologist's perspective.

Area of Science:

• Cardiology
• Interventional Cardiology
• Cardiac Surgery

Background:

• Left ventricular outflow tract obstruction (LVOTO) is a common complication in patients with hypertrophic cardiomyopathy (HCM).
• Medical management with beta-blockers, disopyramide, and novel myosin inhibitors (mavacamten, aficamten) is the first line of therapy.
• Septal reduction therapy is indicated for symptomatic patients refractory to medical management.

Purpose of the Study:

• To compare the long-term outcomes and procedural considerations of surgical myectomy and alcohol septal ablation for treating LVOTO in HCM.
• To delineate patient-specific factors influencing the choice between surgical myectomy and alcohol septal ablation.

Main Methods:

• Comparative analysis of outcomes following surgical myectomy and alcohol septal ablation in patients with HCM-related LVOTO.
• Review of procedural success rates, complication profiles, and long-term efficacy of both septal reduction techniques.

Main Results:

• Surgical myectomy and alcohol septal ablation demonstrate comparable long-term outcomes.
• Surgical myectomy is associated with a lower incidence of heart block and a lower residual gradient.
• Specific anatomical features (e.g., mitral valve disease, thickened septum) favor surgical myectomy, while high surgical risk favors alcohol septal ablation.

Conclusions:

• Both surgical myectomy and alcohol septal ablation are effective septal reduction therapies for HCM-induced LVOTO.
• The choice of procedure should be individualized based on patient anatomy, comorbidities, surgical risk, and patient preference.
• Shared decision-making is crucial for optimizing treatment selection in HCM patients with LVOTO.